Nomic Bio

Nomic Bio aims to revolutionize protein profiling, mirroring Illumina's impact on DNA sequencing. Their primary innovation, the nELISA, represents a next-generation immunoassay platform, significantly enhancing the traditional ELISA method by offering higher throughput, greater content richness, and increased versatility. Currently, Nomic Bio provides the nELISA to high-throughput drug discovery scientists through early access programs, enabling them to analyze hundreds of proteins with a tenfold increase in throughput and a tenfold reduction in cost compared to existing methodologies. These programs target HTS groups within leading pharmaceutical companies and innovative biotechnology firms. The overarching objective is to establish a universally adopted technology that replaces the diverse array of legacy immunoassay tools currently used by scientists. Nomic Bio envisions a single, comprehensive platform capable of supporting scientific endeavors from initial discovery phases through clinical applications. Their team comprises engineers, biologists, and skilled laboratory operators, all focused on expanding rapidly to meet growing customer demand. They are also dedicated to further developing their core technology, scaling multiplexing and throughput capabilities, and building a robust software infrastructure. Nomic Bio is actively recruiting for various positions across engineering, software development, biology, and operations.